去甲长春花碱、多西紫杉醇、吉西他滨治疗晚期非小细胞肺癌

Advanced Nonsmall cell lung cancer treatment with Vinorelbine, Docetaxel, Gemcitabine combined with Cisplatine, respectly: a report of 95 patients

目的 观察去甲长春花碱 (Vinorelbine商品名 :诺维本Navelbine ,NVB) ,多西紫杉醇 (Docetaxel商品名 :泰索帝 ) ,吉西他滨(Gemcitabine商品名 :健择 )分别联合顺铂 (Cisplatin)治疗晚期非小细胞肺癌的疗效及其毒副反应。方法 95例晚期非小细胞肺癌患者分别接受由诺维本、泰索帝、健择联合顺铂 (NP、DP、GP)组成的方案 ,其中NP方案 35例 ,DP、GP方案均分别为 30例 ,三组间患者特征具有可比性。结果 NP组中 ,无CR病例 ,PR4 2 .9% ,NC4 0 % ,PD17.1%RR4 2 .9% ;DP组中CR3.3% ,PR4 0 % ,NC4 0 % ,PD16 .7% ,RR4 3.3% ;GP组中CR无 ,PR4 6 .7% ,NC4 0 % ,PD13.3% ,RR4 6 .7%。其毒副反应 :主要均为血液学毒性 ,其中 ,NP组和DP组以白细胞减少为主 ,GP组以血小板减少为主。结论 NP、DP、GP方案治疗晚期非小细胞肺癌疗效相似 ,其主要毒副反应是骨髓抑制 ,但均可耐受。

Objective To observe the effectiveness and the toxicity of Vinorelbin, Docetaxel or Gemcitabine combined with Cisplatin, (ie: NP? DP or GP regime) in patients with advanced non-small cell lung cancer. Methods 95 patients were enrolled in this study. 35 patients recevied NP, 30 patients recevied DP, 30 patients recervied GP. Results In the NP group, no CR case, 15 PR cases(42.9%), In the DP group, 1 CR case 12 PR cases(43.3%), In the GP group, there were 14PR cases(46.7%). The major side effect was due to hematologic toxicty. The leucopenia was higher in the NP group. The thrombocytopenia was higher in the GP group. Conclusion The effectiveness of NP, DP, GP regimens in the treatment advanced non-small cell lung cancer shows no significant different. The major toxicity is hematolgic side effects.